GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pasithea Therapeutics KTTA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.54

-6.31%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2020FY2025

Net income

−$20.4m

FY2020FY2025

Free cash flow

−$15.2m

FY2020FY2025

Shareholders' equity

$55.2m

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Revenue——$486,559$486,559$15,062—
Gross profit−$662,585−$649,029−$648,454−$5,094−$2,213—
Research and development$8.0m$7.2m$8.1m$2.7m——
Operating income−$20.9m−$14.2m−$16.0m−$12.6m−$4.5m−$61,476
Net income−$20.4m−$13.9m−$16.0m−$13.9m−$2.2m−$61,476
Diluted earnings per share-2.91-12.69-15.32-10.70-1.89-0.16

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assets$60.2m$16.1m$26.1m$45.2m$53.3m$247,958
Cash and short-term investments$55.2m$6.9m$16.3m$33.1m$53.0m$243,650
Total liabilities$5.0m$1.3m$2.7m$2.7m$1.9m$6,603
Debt——$81,680$504,383——
Shareholders' equity$55.2m$14.8m$23.4m$42.5m$51.4m$241,355
Shares outstanding7m1m1m1m1m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−$15.2m−$13.9m−$13.4m−$13.7m−$3.2m−$38,689
Capital spending—−$2−$34,301−$107,102−$21,503−$1
Free cash flow−$15.2m−$13.9m−$13.5m−$13.8m−$3.2m−$38,690
Dividends paid—−$359.7m————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——————$649,028—
Gross profit−$157,541−$157,541−$157,962−$181,541−$161,745−$161,707−$162,258−$162,257
Operating income−$5.7m−$4.9m−$10.3m−$3.1m−$3.8m−$3.7m−$3.3m−$3.0m
Net income−$5.3m−$2.9m−$10.1m−$3.0m−$3.7m−$3.6m−$3.2m−$3.0m
Diluted earnings per share-0.75-0.41-1.44-0.43-0.53-0.51-2.90-2.74
Cash from operations−$4.0m−$4.0m−$5.0m−$2.0m−$3.0m−$3.0m−$2.0m−$3.0m
Total assets$51.7m$56.4m$60.2m$13.6m$17.0m$14.7m$16.1m$18.6m
Cash and short-term investments$45.66bn$50.4m$55.2m$4.1m$7.2m$5.3m$6.9m$9.4m
Debt————$155,455$268,969——
Shareholders' equity$49.8m$54.8m$55.2m$12.2m$15.2m$13.0m$14.8m$17.8m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income18.3%220.7%—
Net income13.6%219.4%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-0.4-0.3-0.5-1.2-18.7
Price to sales——15.834.4—

Share price return

Finished calendar years

20252024202320222021
Return-57%-61%-57%-48%-60%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-to-1 reverse split · 2 Jan 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.